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tients with potentially resectable PC. In the adjuvant treat-
ment after curative-intent surgery, gemcitabine (Gem) is 
regarded as standard of care by 71% after R0 resection and 
62% after R1 resection. For patients with locally advanced 
PC, 52% of the participating centers recommend systemic 
chemotherapy, 17% prefer combined primary chemoradio-
therapy. Most centers (59%) base their decision of combina-
tion regimens for metastatic disease on the performance 
status of their patients. In patients with a good status, 28% 
apply single-agent Gem, 3% use Gem + capecitabine, 12% 
Gem + erlotinib, 16% Gem + oxaliplatin, and 8% Gem + cis-
platin. Only 28% of the survey doctors offer second-line 
treatment to the majority of their patients with advanced PC. 
 Conclusion: Not every PC patient in Germany is treated ac-
cording to the present S3 guidelines. Diagnosis and treat-
ment of PC in Germany still need to be improved. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Pancreatic adenocarcinoma (PC) still remains a dis-
ease with a dismal prognosis. In 2007 in the United States, 
an estimated 37,170 new PC cases were diagnosed, with a 
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 Abstract 
 Background: No data have previously been available re-
garding the current treatment of patients with pancreatic 
cancer (PC) in German hospitals and medical practices. 
 Methods: Between February 2007 and March 2008 we con-
ducted a national survey [on behalf of the Arbeitsgemein-
schaft Internistische Onkologie (AIO) and the Chirurgische 
Arbeitsgemeinschaft Onkologie (CAO)] regarding the cur-
rent surgical and oncological treatment of PC in Germany. 
Standardized questionnaires were sent via mailing lists to 
members of the AIO and CAO (n = 1,130). The data were ana-
lyzed using SPSS software (version 16.0). Pre-defined sub-
group analysis was performed by grouping the results of 
each question with regard to the professional site of the re-
sponding physician and to the number of patients treated in 
their institution by year.  Results: 181 (16%) of the oncological 
questionnaires were sent back. For 61% of the participating 
centers, a histological confirmation of PC diagnosis is oblig-
atory. 21% of physicians offer neoadjuvant therapy to pa-
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nearly identical estimated rate of deaths (33,370)  [1] . For 
patients with resectable disease at diagnosis, radical sur-
gical tumor resection still is regarded as the only option 
for long-term survival or cure. In patients with locally 
advanced (unresectable) or metastatic PC, palliative sys-
temic chemotherapy is the international standard of care 
 [2, 3] .
 Since the introduction of the nucleoside analogue 
gemcitabine in the treatment of PC, several phase III tri-
als have evaluated the role of a gemcitabine-containing 
combination treatment for patients with advanced dis-
ease  [2, 4] . To date, only the combination of gemcitabine 
with the anti-EGFR tyrosine kinase inhibitor erlotinib 
provided a statistically significant (but clinically moder-
ate) survival benefit compared to single-agent gemci ta-
bine  [5] . Promising efficacy results were also obtained 
with cytotoxic combinations of gemcitabine plus the oral 
fluoropyrimidine capecitabine or a platinum analogue 
 [6–9] . However, based on the currently available data, it 
seems that only a subgroup of patients may derive a sig-
nificant survival benefit from those cytotoxic combina-
tion regimens, e.g. those with metastatic disease and a 
good performance status at treatment initiation  [10, 11] . 
For patients with locally advanced disease, the role of lo-
cal radiotherapy (added to standard chemotherapy) still 
remains controversial  [12] . Potentially, a sequential treat-
ment approach (initial treatment with systemic chemo-
therapy for distant disease control, followed by chemora-
diotherapy for local control) could be an effective thera-
peutic option for those patients  [13, 14] .
 Based on clinical research conducted in patients with 
an advanced stage of disease, and on the poor prognosis 
of PC even after complete surgical resection, adjuvant 
treatment concepts have become a focus in recent years. 
Currently, adjuvant chemotherapy (e.g. with single-agent 
gemcitabine) is regarded as the standard of care (at least 
in European countries) after curative-intent surgery 
with a statistically significant benefit for disease-free 
and overall survival  [15–17] . However, in the United 
States, there is still a trend towards the use of adjuvant 
chemoradiotherapy – despite the fact that this treatment 
approach has not shown a consistent survival advantage 
(compared to best supportive care only) in large ran-
domized controlled trials to date  [18, 19] . Phase III trials 
evaluating neoadjuvant treatment regimens for (poten-
tially) resectable PC are currently under way, but to date 
only data from phase II neoadjuvant studies are available 
 [20, 21] . Thus, a neoadjuvant treatment approach should 
have no place in the daily routine treatment of localized 
PC.
 The aim of this study was to evaluate (based on a na-
tional survey using standardized questionnaires) the 
clinical practise of PC diagnosis, treatment and follow-up 
in German hospitals and medical practices. The obtained 
results were specifically analysed within the context of 
the recently published German S3 guideline ‘exocrine 
pancreatic cancer’, which contains consensus-based rec-
ommendations for prevention/screening, diagnosis and 
treatment of PC  [3] .
 Materials and Methods 
 Survey Design and Questionnaire 
 From February 2007 to March 2008 standardized question-
naires regarding the surgical and oncological treatment of PC 
were sent by mail, fax and e-mail to German hospitals (university 
and community hospitals) and medical practices. The study ques-
tionnaire was designed by C.J. Bruns and K.-W. Jauch (surgical 
section) and S. Boeck and V. Heinemann (oncological section). In 
this paper, we report only on the results from the oncological part, 
as the surgical results from the survey will be published separate-
ly. The main goal of the questionnaire was to inquire into the local 
standards for PC diagnosis and treatment at the participating 
centers. The questionnaire was grouped in 3 parts. (1) Data of the 
participating physician: medical area of work (e.g. surgeon, gas-
troenterologist, medical oncologist), professional site (e.g. univer-
sity or community hospital, private practice), and number of PC 
patients treated per year. (2) Questions on the local standard di-
agnostic procedures for PC. (3) Questions on the local treatment 
standards for resectable (including neoadjuvant and adjuvant 
therapy) and advanced PC. Both multiple-choice and open ques-
tions were part of the survey.
 Participating Physicians 
 During the 1 year of evaluation, 1,130 questionnaires were sent 
out. The participating centers were not pre-selected, we contacted 
all members of the AIO gastrointestinal cancer study group and 
all members of the CAO of the German Cancer Society (DKG). 
All participating AIO/CAO physicians were contacted via e-mail 
lists. Additionally, all members of the project group ‘Gastrointes-
tinal Tumors’ (chair: C.J. Bruns) of the Tumorzentrum München 
were contacted via mail and fax and participation in the national 
AIO/CAO survey was offered to physicians registered in this local 
project group.
 Finally, the questionnaire was also published in the journal  Z 
Gastroenterol (2007; 45: 1340–1342) of the Deutsche Gesellschaft 
für Verdauungs- und Stoffwechselkrankheiten and the readers 
were encouraged to complete the questions and to fax them back 
to the study center at the University of Munich. 
 Statistical Analyses 
 All returned questionnaires were collected centrally at the 
University of Munich and data was entered into an electronic da-
tabase. Study data was analyzed using SPSS  software (version 
16.0) and the Microsoft Office  package (Excel database). Pre-de-
fined subgroup analysis was performed by grouping the results of 
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each question with regard to the professional site of the respond-
ing physician (university hospital vs. community hospital vs. pri-
vate practice) and to the number of patients treated in their insti-
tution by year ( ! 5 patients vs. 11–30 patients vs.  1 30 patients).
 Results 
 Participants in the Survey 
 From the 1,130 questionnaires that were sent out, 181 
questionnaires (16%) concerning the onclogical part of 
the survey were completed and returned. The main re-
sponders were medical oncologists (35.4%), surgeons 
(30.4%) and gastroenterologists (15.5%). Further, 14.9% of 
the returned questionnaires were answered by interdisci-
plinary teams of physicians. Most of the participating 
physicians came from community hospitals (49.7%), fol-
lowed by university hospitals (27.6%) and physicians in 
private practice (19.9%).
 Of the responders, 9.9% stated that they treat fewer 
than 5 PC patients each year, 33.1% see 11–20, 19.3% see 
21–30, 12.7% see 31–40, 6.6% see 41–50 and 17.7% treat 
more than 50 PC patients per year at their institution. 
 Diagnosis of PC 
 For the establishment of PC diagnosis, 60.8% of the 
responding physicians state that a histological confirma-
tion is necessary. For 37.0%, an elevation of the tumor 
marker CA 19-9 plus a tumor in the pancreas (on imag-
ing, e.g. CT or MRI) is sufficient for the diagnosis of PC. 
Most of the centers use a CT or ultrasound-guided meth-
od (80.7%) for tumor biopsy and histological assessment 
of the specimen; a further 54.1% also use endosonograpy 
techniques for needle biopsies of the primary tumor in 
the pancreas.
 Resectable PC and Adjuvant Treatment 
 Only 1 doctor (0.6%) would not recommend a radical 
surgical resection for a patient with resectable PC; 29.3% 
would recommend a pylorus-preserving operation tech-
nique and 41.4% a classical Whipple procedure. For the 
remaining 25.4%, both procedures seem suitable as stan-
dard treatment for a patient with resectable disease.
 Of the centers in this survey, 2.8% always perform a 
neoadjuvant treatment in each patient with resectable 
disease, whilst 30.4% never perform neoadjuvant treat-
ments. Another 43.1% of physicians are treating their pa-
tients with neoadjuvant therapy only within clinical tri-
als, for 17.7% the decision is individual in each case. If the 
centers decided to proceed to neoadjuvant therapy, most 
of them (57.7%) apply neoadjuvant chemoradiotherapy, 
36.5% would prefer neoadjuvant chemotherapy alone.
 The survey results for treatment decisions in the adju-
vant setting are summarized in  table 1 .
 Advanced PC 
 Locally Advanced Disease . In patients with locally ad-
vanced PC (unresectable, but without distant metastasis), 
2.8% of the participating colleagues would recommend 
no antitumor treatment at all. For 51.9%, chemotherapy 
is the local standard of care in this patient population, 
16.6% prefer a combined chemoradiotherapy. Ten doc-
tors (5.5%) would treat their patients sequentially, 3 with 
radiotherapy followed by chemotherapy and 7 with che-
motherapy followed by radiotherapy. No participant se-
lected the term ‘radiotherapy only’.
Table 1. Adjuvant therapy after curative-intent resection of PC
(n = 181)
Treatment decision R0 resection R1 resection1
No adjuvant therapy 27 (14.9%) 5 (2.8%)
Gemcitabine 129 (71.3%) 112 (61.9%)
5-FU/FA (Mayo regimen) 0 (0%) 0 (0%)
Chemoradiotherapy 4 (2.2%) 25 (13.8%)
Other treatment 20 (11.0%) 10 (5.5%)
1 The remaining 27 physicians (14.9%) selected multiple an-
swers. 
Table 2. Palliative chemotherapy in patients with metastatic PC 
(n = 181)
Treatment decision Good perfor-
mance status
(KPS 90–100%)
Poor perfor-
mance status
(KPS ≤80%)
Single-agent gemcitabine 50 (27.6%) 123 (68.0%)
Single-agent 5-FU 1 (0.6%) 3 (1.7%)
Single-agent capecitabine 1 (0.6%) 1 (0.6%)
Gemcitabine + capecitabine 6 (3.3%) 12 (6.6%)
Gemcitabine + erlotinib 21 (11.6%) 8 (4.4%)
Gemcitabine + oxaliplatin 28 (15.5%) 1 (0.6%)
Gemcitabine + cisplatin 15 (8.3%) 0 (0%)
Other treatment 49 (27.1%)1 17 (9.4%)1
1 The remaining physicians (10 and 16, respectively) selected 
none of the above answers. 
KPS = Karnofsky performance status.
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 Metastatic Disease and Palliative First-Line Chemo-
therapy . In patients with metastatic PC, 23.2% of the re-
sponding doctors always treat their patients with a mono-
chemotherapy regimen. 6.1% always apply combination 
therapy regimens, whilst a further 59.1% offer a combina-
tion treatment only to patients with a good performance 
status. The remaining centers selected the answer option 
‘other treatment’. The question when to start chemother-
apy in this patient population was answered with ‘after 
first diagnosis of metastatic PC’ by 86.2%, and with ‘if the 
patient shows clinical symptoms’ by 7.7%.
 The survey results for treatment decisions in the met-
astatic setting (subgroups based on performance status) 
are summarized in  table 2 .
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 Fig. 1. Distribution of frequency of treat-
ing PC patients, by type of professional 
site.  
 Fig. 2. Adjuvant treatment after curative-
intent surgery for resectable PC, by profes-
sional site.  a R0 resection.  b R1 resection.  
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 Concerning the duration of palliative chemotherapy 
in metastatic PC, 66.9% stated that they treat their pa-
tients until tumor progression, whereas 13.3% continue 
chemotherapy only until the control of tumor-related 
symptoms. Another 8.8% offer their patients a pre-de-
fined number of treatment cycles.
 Second-Line Chemotherapy . Only 2 responding cen-
ters (1.1%) always refuse to apply second-line treatment 
after failure of first-line chemotherapy. For most of the 
doctors (65.2%) second-line treatment is an individual 
decision based on the performance status of the patient; 
27.6% offer second-line therapy to the majority of their 
patients. Regimens used in the second-line setting are 
single-agent 5-FU (8.3%), single-agent capecitabine 
(14.9%) or 5-FU/FA + oxaliplatin (34.8%).
 Follow-Up 
 Imaging.  For 6.6% of the participating centers, a clinical 
follow-up after curative-intent surgery for PC is not a local 
standard of care. The remaining centers offer their patients 
follow-up imaging investigations, mainly ultrasound 
 (every 3 months, 31.5%) and CT scan (every 3 months, 
16.6%). A smaller number of colleagues perform follow-up 
imaging with a prolonged time interval (4.4% ultrasound 
every 6 months, 12.2% CT scan every 6 months).
 Serum Tumor Marker.  Most of the responding centers 
also apply tumor markers (e.g. CA 19-9 or CEA) in the 
follow-up of patients after PC resection: 85.1% regularly 
measure tumor markers after surgery, only 9.4% do not 
use tumor marker monitoring at all.
 Subgroup Analyses 
 Influence of the Professional Site of the Responding Phy-
sician on Treatment Decisions. In PC treatment, large-
volume centers ( 1 50 patients per year) are mainly located 
at German university hospitals ( fig. 1 ). Most of the medi-
cal practices treat about 5–20 patients each year. The sur-
vey results for treatment decision in the adjuvant setting 
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site.  a Monotherapy vs. combination ther-
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(after R0 and R1 resections), subgrouped by professional 
sites, are summarized in  figure 2 .  Figure 3 shows the local 
treatment standards of the participating centers for PC 
patients with metastatic disease by professional sites 
( fig. 3 a) and the treatment regimens in patients with good 
performance status ( fig. 3 b).
 Influence of the Number of Patients Treated at an Insti-
tution (by Year) on Treatment Decisions. As outlined in 
 figure 4 , the number of patients treated per year at an in-
stitution seems to have a significant impact on treatment 
decisions for adjuvant therapy. Centers with fewer than 5 
patients/year more frequently recommend no adjuvant 
treatment after R0 tumor resection ( fig. 4 a), and they 
seem to prefer adjuvant chemoradiotherapy after R1 re-
section ( fig. 4 b). In patients with metastatic disease, the 
frequency of single-agent therapy is higher in low-volume 
centers ( fig. 5 a).  Figure 5 b summarizes the treatment reg-
imens offered to patients with metastatic disease and a 
good performance status, divided into subgroups by 
number of patients treated per year. 
 Discussion 
 The progress in the treatment of patients with PC dur-
ing the last 10 years has been steady but slow. However, 
several new treatment options are available now for PC 
patients, including an improvement in surgical tech-
niques, the use of newer chemotherapeutic agents (gem-
citabine) in the adjuvant and palliative setting and re-
cently the new oral anti-EGFR tyrosine kinase inhibitor 
erlotinib has been approved in the EU for the treatment 
of patients with metastatic disease  [2, 3] . Nevertheless, it 
still remains unclear how many PC patients in Germany 
actually do have access to treatment protocols according 
to the current S3 guidelines published in 2007  [3] .
 For this AIO/CAO national survey, 181 German cen-
ters (university hospitals, community hospitals and med-
ical practices) returned a completed questionnaire on 
their local standards for PC diagnosis and treatment. For 
37% of the participants, a histological confirmation of the 
diagnosis of a suspected (advanced) adenocarcinoma of 
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the pancreas was not regarded as necessary. These physi-
cians treat their patients based on imaging (e.g. CT scan) 
and laboratory (e.g. CA 19-9 elevation) findings. This ap-
proach is contrary to the recommendation of the S3 
guideline and contains a significant risk of treating pa-
tients with, for example, an endocrine tumor of the pan-
creas with ineffective gemcitabine chemotherapy  [3] . The 
serum tumor marker CA 19-9 has no diagnostic utility in 
PC, and several confounders may lead to a false-positive 
elevation of CA 19-9 levels  [22] . Also in the neoadjuvant 
setting, a significant proportion (21%) of German onco-
logical centers treat their patients without an evidence-
based rationale for this therapy. To date, no scientific ev-
idence exists that a neoadjuvant treatment (chemothera-
py and chemoradiotherapy) provides a survival benefit 
for patients with (potentially) resectable disease  [20] . 
Phase II data showed the feasibility of such an approach, 
but randomized studies are still lacking and thus neoad-
juvant therapy should currently have no place – outside 
controlled clinical trials – in daily clinical practice  [21] .
 Significant progress in the treatment of resectable PC 
was the introduction of adjuvant chemotherapy as a new 
standard of care  [20] . Two large European randomized 
phase III trials recently showed that adjuvant chemother-
apy may provide a statistically significant (and clinically 
meaningful) benefit for disease-free and overall survival 
in PC  [15–17] . Interestingly, in Germany, the vast major-
ity of centers already offers their patients adjuvant gem-
citabine chemotherapy (according to the CONKO-001 
trial  [16, 17] ), and nearly no doctors recommend adjuvant 
chemotherapy according to the ‘Mayo regimen’ (bolus 5-
FU plus folinic acid, ESPAC-1 study  [15] ) to their PC pa-
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tients ( table 1 ). However, from a scientific point of view, 
an evidence-based recommendation for the preferred 
chemotherapy regimen will not be possible until the re-
sults of the ESPAC-3 study (gemcitabine vs. 5-FU/FA) be-
come available. It is noteworthy that there are still centers 
not offering adjuvant therapies at all (about 18%), and af-
ter R1 resection about 14% of the survey centers recom-
mend chemoradiotherapy as their treatment of choice 
 [18, 19] . 
 For palliative treatment of advanced disease, single-
agent gemcitabine is still regarded as a standard of care, 
especially in patients with a poor performance status ( ta-
ble 2 ). The combination of gemcitabine plus erlotinib (ap-
proved in Germany in January 2007) was selected as their 
treatment of choice by only 12% (for patients with good 
performance status) and 4% (for patients with poor per-
formance status) of the survey doctors. Perhaps this low 
selection rate for gemcitabine plus erlotinib was also in-
fluenced by the fact that our survey was initiated in Feb-
ruary 2007, a time point when erlotinib had just received 
regulatory approval in Germany. The combination of 
gemcitabine with a platinum compound (e.g. cisplatin or 
oxaliplatin) is mainly restricted to patients with a good 
performance status ( table 2 ). However, such a treatment 
decision is only based on post-hoc subgroup analyses 
from randomized phase III trials that suggest a survival 
benefit for combination chemotherapy in good perfor-
mance status patients  [23] . Prospective trials for an evi-
dence-based recommendation of this treatment decision 
are lacking. Second-line therapy was not regarded as an 
international standard of care for all patients with PC at 
the time this survey was conducted  [24] . This is also re-
flected by the survey results, with most doctors regarding 
salvage chemotherapy as an individual treatment deci-
sion. A randomized study, presented as an abstract at the 
ASCO meeting in 2008, was the first to provide prelimi-
nary evidence for a survival benefit with the use of sec-
ond-line therapy after failure of first-line gemcitabine 
 [25] .
 The role of follow-up investigations after curative-in-
tent surgery is discussed controversially for different 
types of malignant tumors. In Germany, most centers 
offer their patients regular follow-up investigations after 
PC surgery, with imaging and also tumor marker moni-
toring  [26–28] . To date, it remains unclear if a survival 
benefit could be obtained for PC patients with the use of 
such (expensive) follow-up methods. The pre-defined 
subgroup analyses of this national AIO/CAO survey 
( fig. 1–5 ) suggest that treatment decisions are influenced 
by both the number of patients treated in an institution 
per year and by the professional site of the responding 
physician. However, these results should rather be re-
garded hypothesis-generating than definitive. The main 
limitations for interpretation of the data derived from 
this national multicenter survey arise from the fact that 
an unexpectedly low number of questionnaires were re-
turned (16%) and that there may be a possible selection 
bias with the invitation to members of the AIO and CAO. 
Thus, when interpreting the presented data, one should 
be aware of these possible confounders, which also apply 
to the above named subgroup analyses from this sur-
vey.
 In conclusion, this national AIO/CAO survey provides 
evidence that there is still room for an improvement in 
the treatment of patients with PC in Germany. The cur-
rent S3 guidelines are not applied in each hospital/prac-
tice in Germany, and a combined effort of each partici-
pant in the public health system seems necessary to offer 
each of our patients the current international standard of 
care for his/her disease.
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